Bannister, Mark L., Alvarez-Laviada, Anita, Thomas, N. Lowri ![]() ![]() |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Flecainide is a use-dependent blocker of cardiac Na+ channels. The mechanisms involved in block were elucidated using fully charged (QX-FL) and neutral (NU-FL) derivatives of flecainide, establishing that Na+ channel block requires the cationic form of the molecule to enter the cytosolic vestibule of the open channel. Flecainide is also effective in the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), however its mechanism of action is contentious. We investigated how flecainide derivatives influence RyR2-mediated Ca2+-release from the sarcoplasmic reticulum and whether this correlates with their effectiveness as blockers of Na+ channels and/or RyR2.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Subjects: | R Medicine > R Medicine (General) |
Additional Information: | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) licence |
Publisher: | Wiley |
ISSN: | 0007-1188 |
Funders: | British Heart Foundation |
Date of First Compliant Deposit: | 15 June 2016 |
Date of Acceptance: | 17 May 2016 |
Last Modified: | 11 Oct 2023 21:39 |
URI: | https://orca.cardiff.ac.uk/id/eprint/91718 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |